Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Text Size
894 studies found for:    "Mantle cell lymphoma"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
21 Unknown † Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma Recurrent
Intervention: Drug: Combination of Bortezomib, Fludarabine and Cyclophosphamide
22 Withdrawn A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: acalabrutinib;   Drug: ibrutinib;   Drug: rituximab
23 Completed Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: Iodine-131 Anti-B1 Antibody;   Drug: Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP)
24 Active, not recruiting A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: Bendamustine;   Drug: Rituximab;   Drug: Ibrutinib;   Drug: Placebo
25 Recruiting Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: Ibrutinib;   Drug: bortezomib
26 Terminated Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Intervention: Drug: Fludarabine, Mitoxantrone, Dexamethasone, Vorinostat
27 Completed Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Intervention: Drug: 90Y-ibritumomab tiuxetan (Zevalin)
28 Active, not recruiting Study of LY2835219 for Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Intervention: Drug: LY2835219
29 Unknown † Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma
Condition: Mantle-Cell Lymphoma
Interventions: Drug: Immunochemotherapy;   Drug: High-dose BEAM plus autologous SCT;   Other: HLA-identical allogenic SCT
30 Active, not recruiting An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Condition: Relapsed or Refractory Mantle Cell Lymphoma
Intervention: Drug: Ibrutinib
31 Completed Oral Enzastaurin HCl in Patients With Relapsed Mantle Cell Lymphoma
Condition: Mantle-Cell Lymphoma
Intervention: Drug: enzastaurin
32 Completed VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Intervention: Drug: VELCADE TM (bortezomib) for Injection
33 Recruiting ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)
Condition: Mantle Cell Lymphoma
Interventions: Drug: ABT-199;   Drug: Ibrutinib
34 Active, not recruiting Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: PD 0332991;   Drug: bortezomib
35 Active, not recruiting
Has Results 		Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: Rituximab;   Drug: Bendamustine;   Drug: Cytarabine
36 Terminated
Has Results 		Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma
Condition: Mantle-Cell Lymphoma
Intervention: Drug: Rituximab, Bortezomib,Y90 ibritumomab tiuxetan
37 Completed A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Intervention: Drug: AT7519M
38 Not yet recruiting Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)
Condition: Mantle-Cell Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Venetoclax;   Drug: Placebo Oral tablet to match Venetoclax
39 Terminated Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Intervention: Drug: Fludarabine, Mitoxantrone and Rituximab
40 Recruiting A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients
Condition: Mantle Cell Lymphoma
Intervention: Drug: Ibrutinib + GA101 +GDC-0199
To Top

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
† Study has passed its completion date and status has not been verified in more than two years.